Biologics beyond Anti-TNF Agents for Ulcerative Colitis - Efficacy, Safety, and Cost?

N Engl J Med. 2019 Sep 26;381(13):1279-1281. doi: 10.1056/NEJMe1910742.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal, Humanized
  • Biological Products*
  • Colitis, Ulcerative*
  • Humans
  • Tumor Necrosis Factor-alpha

Substances

  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Tumor Necrosis Factor-alpha
  • vedolizumab
  • Adalimumab